Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome

  1. Juan Gómez
  2. Guillermo M. Albaiceta
  3. Marta García-Clemente
  4. Carlos López-Larrea
  5. Laura Amado-Rodríguez
  6. Inés Lopez-Alonso
  7. Tamara Hermida
  8. Ana I. Enriquez
  9. Pablo Herrero
  10. Santiago Melón
  11. Marta E. Alvarez-Argüelles
  12. José A. Boga
  13. Susana Rojo-Alba
  14. Elías Cuesta-Llavona
  15. Victoria Alvarez
  16. Rebeca Lorca
  17. Eliecer Coto

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.gene.2020.145102
  2. ScreenIT

    SciScore for 10.1101/2020.06.11.20128033: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: The study was approved by the Ethics Committee of Principado de Asturias (Oviedo, Spain).
    Consent: All the patientsor their representatives gave their consent to participate.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study has several limitations, mainly the reduced sample size of the patients and of female severe cases in particular. This limits the statistical interpretation of the significant and non-significant associations. Also, we did not study subjects exposed to the virus who did not show disease symptoms. These individuals would be resistant to SARS-Cov-2 infection and are crucial for the identification of gene variants associated with disease susceptibility. In conclusion, our study suggested that the ACE-ID polymorphism was associated with the risk of developing severe COVID19 depending on the hypertension status. The ACE2rs2285666 variant was associated with hypertension in our elderly population, without significant difference between mild and severe COVID19 patients.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.06.11.20128033v1 on medRxiv